Nasdaq:SIGA
SIGA TECHNOLOGIES INC
SIGA Technologies designs and manufactures high-margin, proprietary medical device platforms for complex GI and cardiovascular procedures.
Key Metrics
Investment Thesis
Bull Case
Investors may favor SIGA due to its dominant market position in specialized GI procedures backed by a robust pipeline of next-generation devices that command premium pricing power. The company's ability to generate substantial free cash flow supports significant share buybacks and funding for high-risk, high-reward R&D projects without diluting shareholders. Proprietary platforms create sustainable competitive barriers that protect margins against generic or lower-quality competitors.
Bear Case
Potential investors should be cautious about the cyclical nature of medical device adoption rates which could lead to revenue volatility if key procedures decline. High research and development expenditures combined with regulatory uncertainty pose a risk that new product launches may fail to meet commercial expectations. The company's reliance on specific proprietary technologies makes it vulnerable to breakthrough innovations from larger, better-capitalized competitors entering the same therapeutic areas.
About SIGA TECHNOLOGIES INC
SIGA Technologies Inc. is a leading provider of advanced medical devices focused on gastrointestinal and cardiovascular interventions, serving global markets with innovative platforms like the SIGA® system. The company leverages its proprietary technology to deliver minimally invasive solutions that enhance procedural efficiency and patient outcomes across major healthcare systems.
Analysis
Management Discussion
SIGA reported strong profitability with net income of $59.2M and operating profit of $70.0M, reflecting robust operational leverage from its high-gross-margin device portfolio. While revenue growth moderated slightly in 2024 compared to the prior year, the company maintained a healthy cash position with $155.4M in cash and equivalents while investing heavily in R&D totaling $12.3M to fuel future innovation.
Industry Overview
The medical device industry for gastrointestinal and cardiovascular interventions is characterized by rapid technological advancement and high barriers to entry due to stringent regulatory requirements. Market dynamics are shifting towards value-based care models that prioritize outcomes over volume, rewarding companies with proven efficacy and cost-efficiency in complex procedures.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $110.8M | $139.9M | $138.7M |
| Cost of Revenue | $10.4M | $17.8M | $31.3M |
| Gross Profit | $100.3M | $122.1M | $107.4M |
| Operating Expenses | $57.6M | $38.5M | $37.4M |
| Operating Income | $42.7M | $83.6M | $70.0M |
| R&D | $22.5M | $16.4M | $12.3M |
| G&A | $35.1M | $22.0M | $25.1M |
| Stock-Based Comp | $1.8M | $2.1M | $3.6M |
| D&A | $517.6K | $538.3K | $538.4K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $1.4M | $4.2M | $6.1M |
| Interest Expense | $0 | — | — |
| Pre-Tax Income | $44.1M | $87.8M | $76.1M |
| Income Tax | $10.2M | $19.7M | $16.9M |
| Continuing Ops | $33.9M | $68.1M | $59.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $33.9M | $68.1M | $59.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $33.9M | $68.1M | $59.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $185.8M | $239.0M | $231.0M |
| Cash & Equivalents | $98.8M | $150.1M | $155.4M |
| Accounts Receivable | $45.4M | $21.1M | $21.2M |
| Inventory | $39.3M | $64.2M | $49.6M |
| Prepaid Expenses | $2.3M | $3.5M | $4.9M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $9.2M | $15.4M | $13.3M |
| PP&E (Net) | $1.8M | $1.3M | $1.3M |
| Goodwill | $898.3K | $898.3K | $898.3K |
| Other LT Assets | $6.5M | $13.1M | $11.1M |
| Total Assets | $195.0M | $254.4M | $244.3M |
| Current Liabilities | $21.5M | $54.1M | $25.3M |
| Accounts Payable | $3.4M | $1.5M | $1.3M |
| Current Leases | — | — | $546.8K |
| Deferred Revenue | $10.6M | $20.8M | $10.3M |
| Taxes Payable | $1.3M | $21.7M | $8.0M |
| Other Current Liab | $-10.6M | $0 | $-546.8K |
| Long-Term Liabilities | $3.4M | $3.4M | $3.2M |
| LT Operating Leases | — | — | $800.0K |
| Other LT Liab | — | — | $2.4M |
| Total Liabilities | $24.9M | $57.5M | $28.5M |
| Shareholders' Equity | $170.2M | $196.9M | $215.8M |
| Retained Earnings | $-63.8M | $-38.9M | $-22.8M |
| Total L&E | $195.0M | $254.4M | $244.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $33.9M | $68.1M | $59.2M |
| Non-Cash Adjustments | $35.2M | $-10.1M | $34.1M |
| Working Capital Changes | $-27.5M | $36.9M | $-44.6M |
| Cash from Operations | $41.6M | $94.8M | $48.8M |
| Cash from Investing | $0 | $-21.7K | $-42.5K |
| Debt Repayments | $0 | — | — |
| Share Buybacks | $13.0M | $11.1M | $0 |
| Dividends Paid | $32.9M | $32.1M | $42.7M |
| Cash from Financing | $-46.0M | $-43.4M | $-43.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-4.3M | $51.4M | $5.3M |
| Beginning Cash | $103.1M | $98.8M | $150.1M |
| Ending Cash | $98.8M | $150.1M | $155.4M |
Frequently Asked Questions
How does SIGA TECHNOLOGIES INC make money?
The company's revenue streams are primarily driven by the sale of advanced endoscopic platforms such as the SIGA® system for submucosal dissection, alongside cardiovascular devices including ablation catheters and diagnostic tools. Significant portions of revenue also derive from service fees associated with device usage, maintenance contracts, and international distribution channels that support a diverse portfolio of medical technologies.
What are the main risks for SIGA?
Regulatory approval processes for new medical device indications can be lengthy and costly, potentially delaying market entry or limiting revenue growth from new products. The company faces intense competition in the medical device sector which could lead to pricing pressure or erosion of market share if innovation pipelines stagnate. Dependence on a small number of large customers or key distributors creates concentration risk that could materially impact future sales volumes.
What is SIGA's competitive advantage?
SIGA possesses strong intellectual property protection through its proprietary platforms that are difficult for competitors to replicate without significant R&D investment. The company benefits from high gross margins supported by a unique product lifecycle strategy that emphasizes durable, next-generation devices rather than frequent obsolescence. A specialized sales force with deep clinical expertise ensures superior adoption rates within key hospital networks and physician communities.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.